Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALABA: Abatacept vs hydroxychloroquine in palindromic rheumatism
2017-004543-20Phase 4Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Oct 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of abatacept in palindromic rheumatism (PR) and rheumatoid arthritis (RA) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Progression to rheumatoid arthritis. Started Oct 2018; status: completed.
02
Drugs
abatacept
03
Conditions
palindromic rheumatism (PR)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2017-004543-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004543-20.